Company / Working Capital
ENANTA PHARMACEUTICALS INC Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$155.8M
FY2025
5-year range
$155.8M / $360.0M
FY2021-FY2025
Trend
-35.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 10 years, ranging from $156M in FY2025 to $413M in FY2020.
Based on SEC 10-K filings.
$156M in FY2025 with a 5-year CAGR of -17.7%.
Declined from $360M to $156M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -17.9%
- 5-Year CAGR
- -17.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -17.7%, indicating a declining trend.
- In FY2025, working capital decreased 35.7% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $155.8M | -35.7% |
| FY2024 | $242.3M | -32.7% |
| FY2023 | $360.0M | +27.7% |
| FY2022 | $281.9M | -0.3% |
| FY2021 | $282.8M | -31.5% |
| FY2020 | $412.7M | +8.8% |
| FY2019 | $379.2M | +4.1% |
| FY2018 | $364.4M | +68.0% |
| FY2017 | $216.8M | -3.3% |
| FY2016 | $224.3M | +36.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026